{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:50:55Z","timestamp":1782111055164,"version":"3.54.5"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le SIDA et les H\u00e9patites virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with moderate plasma protein binding and good potential for anatomical sanctuary penetration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Adding doravirine to existing antiretroviral therapy (ART) regimens has led to virological success in two groups of people living with HIV (PLWHIV): those with recent virological rebound (n\u200a=\u200a84) and those with prolonged low-level viremia (LLV, n\u200a=\u200a39). Doravirine was added without any modification to the other ART drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 6\u2005months, 88% of PLWHIV in the recent failure group had achieved virological success, compared to 33% of those in the LLV group. Efficacy was closely tied to the genotypic susceptibility score (GSS), with higher success rates in patients whose regimens retained two or more active drugs. Doravirine resistance mutations were uncommon but occurred more frequently in the LLV group. No significant associations were found between treatment response and CD4 count, nadir, VL zenith or duration of suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support the use of doravirine add-on strategies to rescue virological control without changing the full regimen, particularly when a full regimen change is not feasible and when GSS is favourable. The study highlights the potential of doravirine in tailored salvage therapy strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag191","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:40:57Z","timestamp":1779277257000},"source":"Crossref","is-referenced-by-count":0,"title":["Add-on efficacy of doravirine in PLWHIV with virological failure and low-level viremia"],"prefix":"10.1093","volume":"81","author":[{"given":"Vincent","family":"Calvez","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, Laboratoire de Virologie , Paris F-75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, IAME, AP-HP, H\u00f4pital Bichat-Claude Bernard, (DMU BIOGEM), Service de Virologie , Paris F-75018 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enagnon Kazali","family":"Alidjinou","sequence":"additional","affiliation":[{"name":"Service de Virologie, CHU de Lille , Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3723-4142","authenticated-orcid":false,"given":"Marc","family":"Wirden","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, Laboratoire de Virologie , Paris F-75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Bouvier-Alias","sequence":"additional","affiliation":[{"name":"Service de Virologie, CHU Henri Mondor , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"De Monte","sequence":"additional","affiliation":[{"name":"Service de Virologie, CHU de Nice , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Maillard","sequence":"additional","affiliation":[{"name":"Service de Virologie, CHU de Rennes, Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Montes","sequence":"additional","affiliation":[{"name":"Service de Virologie, CHU de Montpellier, Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Anne","family":"Trabaud","sequence":"additional","affiliation":[{"name":"Service de Virologie, CHU de Lyon, Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-5844","authenticated-orcid":false,"given":"Stephanie","family":"Raymond","sequence":"additional","affiliation":[{"name":"Service de Virologie, CHU de Toulouse, Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Teyssou","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, Laboratoire de Virologie , Paris F-75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2032-4148","authenticated-orcid":false,"given":"Cathia","family":"Soulie","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, Laboratoire de Virologie , Paris F-75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-537X","authenticated-orcid":false,"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie, AP-HP, H\u00f4pital Bichat-Claude Bernard, Universit\u00e9 Paris Cit\u00e9, INSERM, IAME , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord, Inserm, IAME, AP-HP, H\u00f4pital Bichat-Claude Bernard, (DMU BIOGEM), Service de Virologie , Paris F-75018 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevieve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis D\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, Laboratoire de Virologie , Paris F-75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026062202455452600_dkag191-B1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/00498254.2018.1451667","article-title":"Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans","volume":"49","author":"Sanchez","year":"2019","journal-title":"Xenobiotica"},{"key":"2026062202455452600_dkag191-B2","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1093\/infdis\/jix005","article-title":"Perspectives on human immunodeficiency virus (HIV) cure: HIV persistence in tissue","volume":"215","author":"Boritz","year":"2017","journal-title":"J Infect Dis"},{"key":"2026062202455452600_dkag191-B3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archneurol.2007.31","article-title":"Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system","volume":"65","author":"Letendre","year":"2008","journal-title":"Arch Neurol"},{"key":"2026062202455452600_dkag191-B4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/QAD.0b013e3283427de3","article-title":"Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy\/ml","volume":"25","author":"Ha\u00efm-Boukobza","year":"2011","journal-title":"AIDS"},{"key":"2026062202455452600_dkag191-B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106898","article-title":"Pillars of long-term antiretroviral therapy success","volume":"196","author":"Taramasso","year":"2023","journal-title":"Pharmacol Res"},{"key":"2026062202455452600_dkag191-B6","author":"US Department of Health and Human Services (DHHS)"},{"key":"2026062202455452600_dkag191-B7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026062202455452600_dkag191-B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (TDF) versus Efavirenz\/Emtricitabine\/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/7\/dkag191\/68568323\/dkag191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/7\/dkag191\/68568323\/dkag191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:45:59Z","timestamp":1782110759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag191\/8712876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":8,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag191","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,3]]},"article-number":"dkag191"}}